RecruitingPhase 2NCT07260175

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Principal Investigator
Salah Al-Batran, Prof. Dr.
Frankfurter Institut für Klinische Krebsforschung IKF GmbH
Intervention
Ivosidenib(drug)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
20252031

Study locations (8)

Collaborators

Servier Deutschland GmbH · Servier Affaires Médicales

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07260175 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials